Q&A: NCI's Henry Rodriguez Says CPTC's Second Phase Will Focus on Applications

ProteoMonitor spoke to Henry Rodriguez, director of the Clinical Proteomic Technologies for Cancer program at NCI, about the recently announced reissuance of funds for the CPTC and what direction the initiative's research will take going forward.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.